Global Presbyopia Market to 2030 - Insight, Epidemiology and Market Forecast - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Presbyopia Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of Presbyopia, historical and forecasted epidemiology as well as Presbyopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Presbyopia market report provides current treatment practices, emerging drugs, Presbyopia market share of the individual therapies, current and forecasted Presbyopia market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Presbyopia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Findings

In the year 2020, the total prevalent case of Presbyopia was 286,994,105 cases in the 7MM which are expected to grow during the forecast period, i.e., 2021-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Presbyopia epidemiology [segmented as Total Prevalent Cases of Presbyopia, Total Diagnosed Cases of Presbyopia, Total Age-specific Cases of Presbyopia, Gender-specific Cases of Presbyopia, Severity-specific Cases of Presbyopia, and Total Treated cases of Presbyopia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Presbyopia Epidemiology

Estimates show that the highest cases of Presbyopia in the 7MM were in the United States, followed by Germany, Japan, Italy, France, the United Kingdom, and Spain in 2020.

• In the United States, the total number of prevalent cases of Presbyopia was 117,369,699 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021-2030.
• In the year 2020, the total prevalent cases of Presbyopia were 134,726,460 cases in EU-5 which are expected to grow during the forecast period, i.e., 2021-2030.
• In Japan, the total number of prevalent cases of Presbyopia was 34,897,947 cases in the year 2020 which are expected to grow during the forecast period, i.e., 2021-2030.

Presbyopia Drug Chapters

The drug chapter segment of the Presbyopia report encloses the detailed analysis of Presbyopia late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Scope of the Report

• The report covers the descriptive overview of Presbyopia, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
• Comprehensive insight has been provided into the Presbyopia epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Presbyopia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Presbyopia market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Presbyopia market.

Report Highlights

• In the coming years, the Presbyopia market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Presbyopia. The launch of emerging therapies will considerably impact the Presbyopia market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Presbyopia.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the Presbyopia market.
• To understand the future market competition in the Presbyopia market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Presbyopia in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Presbyopia market.
• To understand the future market competition in the Presbyopia market.

Companies Mentioned

• Allergan (acquired by AbbVie)
• Eyenovia
• Orasis Pharmaceuticals
• Ocuphire Pharma
• Novartis
• Visus Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bnh4o9